Literature DB >> 3985727

Propranolol for portal hypertension. Evaluation of therapeutic response by direct measurement of portal vein pressure.

W G Rector.   

Abstract

Portal vein pressure was measured before and after a week of oral propranolol hydrochloride therapy in 27 patients with alcoholic liver disease. Mean net portal pressure fell (14.5 +/- 3.3 to 12.5 +/- 4.5 mm Hg), but there was wide variation in individual response to the drug. Simultaneous transhepatic portal vein pressure and wedged hepatic vein pressure were similar before and one hour after a single oral dose of 40 mg of propranolol hydrochloride in six additional patients. Arterial, portal, and hepatic vein oxygen content did not change significantly. Propranolol hydrochloride appears not to dissociate portal and wedged hepatic vein pressure or to impair liver oxygenation. Because of variability of response, the portal hypotensive effect of propranolol should be documented before beginning therapy with the drug.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3985727     DOI: 10.1001/archinte.145.4.648

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  7 in total

Review 1.  The medical prevention of variceal bleeding.

Authors:  D Lebrec
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

2.  Effect of propranolol on portal vein hemodynamics: assessment by duplex sonography and indocyanine green clearance in healthy volunteers.

Authors:  W G Zoller; D R Wagner; J Zentner
Journal:  Clin Investig       Date:  1993-08

3.  Systemic and hepatic hemodynamics in hepatosplenic Manson's schistosomiasis with and without propranolol.

Authors:  S Mies; O B Neto; A Beer; C E Baía; F Alfieri; L M Pereira; M J Sette; S Raia
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

4.  Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.

Authors:  Gamal Shiha; Alaa Ibrahim; Ahmed Helmy; Shiv Kumar Sarin; Masao Omata; Ashish Kumar; David Bernstien; Hitushi Maruyama; Vivek Saraswat; Yogesh Chawla; Saeed Hamid; Zaigham Abbas; Pierre Bedossa; Puja Sakhuja; Mamun Elmahatab; Seng Gee Lim; Laurentius Lesmana; Jose Sollano; Ji-Dong Jia; Bahaa Abbas; Ashraf Omar; Barjesh Sharma; Diana Payawal; Ahmed Abdallah; Abdelhamid Serwah; Abdelkhalek Hamed; Aly Elsayed; Amany AbdelMaqsod; Tarek Hassanein; Ahmed Ihab; Hamsik GHaziuan; Nizar Zein; Manoj Kumar
Journal:  Hepatol Int       Date:  2016-10-06       Impact factor: 6.047

Review 5.  Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence.

Authors:  U Thalheimer; M Mela; D Patch; A K Burroughs
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

6.  Wedged hepatic venous pressure reflects portal venous pressure during vasoactive drug administration in nonalcoholic cirrhosis.

Authors:  T Iwao; A Toyonaga; M Ikegami; M Sumino; K Oho; M Sakaki; H Shigemori; M Nakayama; K Tanikawa
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

7.  A randomised controlled trial of propranolol for the prevention of initial bleeding in cirrhotic patients with portal hypertension. Preliminary results. The Italian Multicenter Project for Propranolol in the Prevention of Bleeding.

Authors:  L Pagliaro; L Pasta; G D'Amico
Journal:  Drugs       Date:  1989       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.